DOP2011000254A - Compuestos de piridazinona - Google Patents
Compuestos de piridazinonaInfo
- Publication number
- DOP2011000254A DOP2011000254A DO2011000254A DO2011000254A DOP2011000254A DO P2011000254 A DOP2011000254 A DO P2011000254A DO 2011000254 A DO2011000254 A DO 2011000254A DO 2011000254 A DO2011000254 A DO 2011000254A DO P2011000254 A DOP2011000254 A DO P2011000254A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- substituent
- piridazinona
- compounds
- substituted
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente invención provee un compuesto que tiene eJ efecto de inhibìr la PDE inhibition, y que es útil como un medìcamento para prevenir o tratar la eschizofrenia o etc. Un compuesto de a fórmula (Jo): donde R1 representa a sustituyente, R2 representa un átomo de hídrógeno, o un sustituyente, R3 representa un átomo de hidrógeno, o un sustituyente, El AniJlo A representa un anitlo aromático que puede estar sustituido, y El Anitlo B representa un anitlo heteroaromático de 5 miembros que puede estar sustituido, o una sal del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20220709P | 2009-02-05 | 2009-02-05 | |
| US21392709P | 2009-07-30 | 2009-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2011000254A true DOP2011000254A (es) | 2011-09-30 |
Family
ID=42398214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2011000254A DOP2011000254A (es) | 2009-02-05 | 2011-08-03 | Compuestos de piridazinona |
Country Status (38)
| Country | Link |
|---|---|
| US (7) | US8354411B2 (es) |
| EP (2) | EP2393360B1 (es) |
| JP (1) | JP5659166B2 (es) |
| KR (1) | KR101730665B1 (es) |
| CN (1) | CN102365020B (es) |
| AR (1) | AR075238A1 (es) |
| AU (1) | AU2010211050B2 (es) |
| BR (1) | BRPI1008498B8 (es) |
| CA (1) | CA2751565C (es) |
| CO (1) | CO6410258A2 (es) |
| CR (1) | CR20110440A (es) |
| DK (1) | DK2393360T3 (es) |
| DO (1) | DOP2011000254A (es) |
| EA (1) | EA020690B1 (es) |
| EC (1) | ECSP11011305A (es) |
| ES (1) | ES2561181T3 (es) |
| GE (1) | GEP20146004B (es) |
| HK (1) | HK1164642A1 (es) |
| HR (1) | HRP20160065T1 (es) |
| HU (1) | HUE027478T2 (es) |
| IL (1) | IL214137A (es) |
| JO (1) | JO3114B1 (es) |
| MA (1) | MA33072B1 (es) |
| ME (1) | ME02337B (es) |
| MX (1) | MX2011008305A (es) |
| MY (1) | MY170610A (es) |
| NZ (1) | NZ594851A (es) |
| PE (1) | PE20110991A1 (es) |
| PL (1) | PL2393360T3 (es) |
| RS (1) | RS54504B1 (es) |
| SG (1) | SG173175A1 (es) |
| SI (1) | SI2393360T1 (es) |
| SM (1) | SMT201600008B (es) |
| TN (1) | TN2011000362A1 (es) |
| TW (1) | TWI457333B (es) |
| UY (1) | UY32417A (es) |
| WO (1) | WO2010090737A1 (es) |
| ZA (1) | ZA201106074B (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200924774A (en) * | 2007-10-26 | 2009-06-16 | Astrazeneca Ab | Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mGluR5 |
| CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
| UY32417A (es) | 2009-02-05 | 2010-08-31 | Takeda Pharmaceutical | Compuestos de piridazinona |
| UY33463A (es) | 2010-06-24 | 2012-01-31 | Takeda Pharmaceutical | Compuestos heterocíclicos fusionados |
| EP2593107A1 (en) * | 2010-07-12 | 2013-05-22 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
| JP5760085B2 (ja) | 2010-08-04 | 2015-08-05 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| JP5800813B2 (ja) | 2010-08-04 | 2015-10-28 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2012018058A1 (ja) | 2010-08-04 | 2012-02-09 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| US9150588B2 (en) | 2010-08-10 | 2015-10-06 | Takeda Pharmaceutical Company Limited | Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors |
| JP2013234123A (ja) * | 2010-09-03 | 2013-11-21 | Taisho Pharmaceutical Co Ltd | ３−ピラゾリル−２−ピリドン誘導体 |
| AU2012219316A1 (en) | 2011-02-18 | 2013-10-03 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A) |
| US9029388B2 (en) | 2011-03-16 | 2015-05-12 | Takeda Pharmaceutical Company Limited | Condensed heterocyclic compound |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| CN103889974B (zh) * | 2011-08-22 | 2017-10-03 | 武田药品工业株式会社 | 放射性标记的化合物和它们在哺乳动物中作为磷酸二酯酶(pde10a)的定量成像的放射示踪剂的用途 |
| JP6169492B2 (ja) | 2011-11-15 | 2017-07-26 | 武田薬品工業株式会社 | ジヒドロキシ芳香族へテロ環化合物 |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| EP2958896B1 (en) * | 2013-02-21 | 2017-08-30 | Takeda Pharmaceutical Company Limited | Production method of pyridazinone compounds |
| EP2975037A4 (en) | 2013-03-15 | 2016-08-10 | Daiichi Sankyo Co Ltd | BENZOTHIOPHENE DERIVATIVE |
| WO2015006689A1 (en) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
| KR102286860B1 (ko) * | 2013-09-12 | 2021-08-05 | 얀센 바이오파마, 인코퍼레이트. | 피리다지논 화합물 및 이의 용도 |
| KR102323515B1 (ko) | 2013-09-12 | 2021-11-05 | 얀센 바이오파마, 인코퍼레이트. | 아자-피리돈 화합물 및 이의 용도 |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| ES2544869B2 (es) * | 2014-03-04 | 2016-01-18 | Universidade De Vigo | Derivados de piridazin-3(2H)-ona inhibidores selectivos de la isoforma B de la monoaminooxidasa |
| CA2943024A1 (en) | 2014-03-18 | 2015-09-24 | Takeda Pharmaceutical Company Limited | Solid dispersion |
| EP3126362B1 (en) | 2014-04-02 | 2022-01-12 | Intermune, Inc. | Anti-fibrotic pyridinones |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| WO2016145103A1 (en) | 2015-03-11 | 2016-09-15 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| WO2016191935A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| BR112018011817A2 (pt) | 2015-12-22 | 2018-12-04 | Jiangsu Hengrui Medicine Co | derivado de benzopiperidina, método de preparação do mesmo, e uso médico do mesmo |
| US10736894B2 (en) | 2018-02-15 | 2020-08-11 | Ovid Therapeutics Inc. | Methods of treating developmental syndromes with PDE10A inhibitors |
| CN108498868B (zh) * | 2018-04-03 | 2020-09-15 | 北京大学口腔医学院 | 具有细胞外基质电学拓扑特征的带电复合膜及其制备方法 |
| CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| WO2019241787A1 (en) * | 2018-06-15 | 2019-12-19 | The Regents Of The University Of Colorado A Body Corporate | Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use |
| JP2022501335A (ja) * | 2018-09-28 | 2022-01-06 | 武田薬品工業株式会社 | 自閉症スペクトラム障害を治療または予防するためのバリポデクト（Ｂａｌｉｐｏｄｅｃｔ） |
| MX2019008440A (es) | 2019-07-15 | 2021-01-18 | Dva Farma Mexicana S A De C V | Composiciones de recubrimientos en pelicula para tabletas con brillantez incrementada, procedimiento de preparacion y aplicacion. |
| GB202002926D0 (en) | 2020-02-28 | 2020-04-15 | Benevolentai Tech Limited | Compositions and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0011693A1 (de) * | 1978-10-03 | 1980-06-11 | Ciba-Geigy Ag | Neue N-(trifluormethansulfonylaminophenyl)-substituierte N-Heterocyclen, ihre Herstellung, sie enthaltende Mittel und ihre Verwendung zur Beeinflussung des Pflanzenwachstums |
| FR2648135B1 (fr) * | 1989-06-07 | 1991-09-27 | Pf Medicament | Derives de phenyl-1-dihydro-1,4 amino-3 oxo-4 pyridazines, leur preparation et leur application en therapeutique |
| GB9506382D0 (en) | 1995-03-29 | 1995-05-17 | Boots Co Plc | Pharmaceutical compositions |
| AU756275B2 (en) | 1998-08-14 | 2003-01-09 | Nihon Nohyaku Co., Ltd. | Pyridazinone derivatives |
| US20070060606A1 (en) * | 1999-10-07 | 2007-03-15 | Robertson Harold A | Compounds and methods for modulating phosphodiesterase 10A |
| GB0013383D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| US20090162286A1 (en) | 2004-06-07 | 2009-06-25 | Pfizer Inc. | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions |
| EP1769092A4 (en) | 2004-06-29 | 2008-08-06 | Europ Nickel Plc | IMPROVED LIXIVIATION OF BASE METALS |
| DK1841757T3 (da) | 2005-01-07 | 2010-09-13 | Pfizer Prod Inc | Heteroaromatiske quinolin-forbindelser og deres anvendelse som PDE10-hæmmere |
| JP4890439B2 (ja) * | 2005-03-07 | 2012-03-07 | 杏林製薬株式会社 | ピラゾロピリジン−４−イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤 |
| CA2654394A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
| TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| EP2219646A4 (en) * | 2007-12-21 | 2010-12-22 | Univ Rochester | METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS |
| WO2010000020A1 (en) | 2008-06-30 | 2010-01-07 | Cathrx Ltd | A catheter |
| TWI396689B (zh) | 2008-11-14 | 2013-05-21 | Amgen Inc | 作為磷酸二酯酶１０抑制劑之吡衍生物 |
| AR074343A1 (es) | 2008-11-14 | 2011-01-12 | Amgen Inc | Derivados de piridina y pirimidina como inhibidores de la fosfodiesterasa 10 |
| SG171954A1 (en) * | 2008-12-04 | 2011-07-28 | Hoffmann La Roche | Pyridazinone derivatives |
| UY32417A (es) * | 2009-02-05 | 2010-08-31 | Takeda Pharmaceutical | Compuestos de piridazinona |
| US9187455B2 (en) * | 2009-02-23 | 2015-11-17 | Hoffmann-La Roche Inc. | Substituted pyridazines as PDE10A inhibitors |
| US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| WO2012018058A1 (ja) * | 2010-08-04 | 2012-02-09 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| US9150588B2 (en) * | 2010-08-10 | 2015-10-06 | Takeda Pharmaceutical Company Limited | Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors |
-
2010
- 2010-02-04 UY UY0001032417A patent/UY32417A/es not_active Application Discontinuation
- 2010-02-04 US US13/148,172 patent/US8354411B2/en active Active
- 2010-02-04 SG SG2011054491A patent/SG173175A1/en unknown
- 2010-02-04 BR BRPI1008498A patent/BRPI1008498B8/pt active IP Right Grant
- 2010-02-04 AR ARP100100304A patent/AR075238A1/es active IP Right Grant
- 2010-02-04 EP EP10738857.1A patent/EP2393360B1/en active Active
- 2010-02-04 AU AU2010211050A patent/AU2010211050B2/en active Active
- 2010-02-04 ES ES10738857.1T patent/ES2561181T3/es active Active
- 2010-02-04 NZ NZ594851A patent/NZ594851A/xx unknown
- 2010-02-04 ME MEP-2016-194A patent/ME02337B/me unknown
- 2010-02-04 MX MX2011008305A patent/MX2011008305A/es active IP Right Grant
- 2010-02-04 WO PCT/US2010/000307 patent/WO2010090737A1/en active Application Filing
- 2010-02-04 TW TW099103286A patent/TWI457333B/zh active
- 2010-02-04 CN CN201080014965.6A patent/CN102365020B/zh active Active
- 2010-02-04 JO JOP/2010/0038A patent/JO3114B1/ar active
- 2010-02-04 KR KR1020117020556A patent/KR101730665B1/ko active IP Right Grant
- 2010-02-04 CA CA2751565A patent/CA2751565C/en active Active
- 2010-02-04 PE PE2011001434A patent/PE20110991A1/es active IP Right Grant
- 2010-02-04 GE GEAP201012363A patent/GEP20146004B/en unknown
- 2010-02-04 SI SI201031103T patent/SI2393360T1/sl unknown
- 2010-02-04 US US12/656,605 patent/US8916566B2/en active Active
- 2010-02-04 JP JP2011549157A patent/JP5659166B2/ja active Active
- 2010-02-04 MA MA34133A patent/MA33072B1/fr unknown
- 2010-02-04 DK DK10738857.1T patent/DK2393360T3/en active
- 2010-02-04 EP EP15192646.6A patent/EP3006031A1/en not_active Withdrawn
- 2010-02-04 EA EA201171004A patent/EA020690B1/ru not_active IP Right Cessation
- 2010-02-04 HU HUE10738857A patent/HUE027478T2/en unknown
- 2010-02-04 RS RS20150859A patent/RS54504B1/en unknown
- 2010-02-04 PL PL10738857T patent/PL2393360T3/pl unknown
- 2010-02-04 MY MYPI2011003610A patent/MY170610A/en unknown
-
2011
- 2011-07-18 IL IL214137A patent/IL214137A/en active IP Right Grant
- 2011-07-22 TN TN2011000362A patent/TN2011000362A1/fr unknown
- 2011-08-03 DO DO2011000254A patent/DOP2011000254A/es unknown
- 2011-08-17 CR CR20110440A patent/CR20110440A/es unknown
- 2011-08-18 ZA ZA2011/06074A patent/ZA201106074B/en unknown
- 2011-08-23 CO CO11106877A patent/CO6410258A2/es active IP Right Grant
- 2011-09-05 EC EC2011011305A patent/ECSP11011305A/es unknown
-
2012
- 2012-05-30 HK HK12105294.8A patent/HK1164642A1/zh unknown
- 2012-07-06 US US13/543,207 patent/US8778944B2/en active Active
- 2012-07-06 US US13/543,296 patent/US8513251B2/en active Active
- 2012-07-06 US US13/543,332 patent/US8435995B2/en active Active
-
2014
- 2014-10-17 US US14/517,313 patent/US9550756B2/en active Active
-
2016
- 2016-01-08 SM SM201600008T patent/SMT201600008B/it unknown
- 2016-01-20 HR HRP20160065TT patent/HRP20160065T1/hr unknown
- 2016-12-13 US US15/377,149 patent/US20170114044A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2011000254A (es) | Compuestos de piridazinona | |
| UY32096A (es) | Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones | |
| CR20130024A (es) | Compuestos heterocíclicos fusionados | |
| CU20120071A7 (es) | DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA | |
| UY33001A (es) | Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina | |
| UY31906A (es) | Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias. | |
| SV2011003809A (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
| ECSP10010271A (es) | Derivados de tiazol usados como inhibidores de pi 3-cinasa | |
| SV2009003373A (es) | COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5- FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA REF. AM102759 | |
| UY33701A (es) | Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina | |
| CO2019004978A2 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| AR081819A1 (es) | Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades | |
| UY32131A (es) | Compuestos de anillo fusionado y uso de los mismos | |
| BR112016023299A8 (pt) | composto tricíclico e inibidor de jak, agente preventivo, terapêutico ou de melhoria para doenças contra as quais inibição de jak é eficaz e para artrite reumatoide, medicamento e utilização desses compostos | |
| BR112012021135A2 (pt) | microbicidas | |
| MX2009005249A (es) | Compuestos organicos. | |
| MX2009004982A (es) | Derivados heterociclicos como inhibidores cetp. | |
| MX2020004842A (es) | Compuestos heterociclicos antiinfecciosos y sus usos. | |
| DOP2011000296A (es) | Compuesto de pirazol | |
| UA106741C2 (uk) | Піридазинони | |
| TH162570A (th) | สารประกอบไพริดาซิโนน | |
| CY1117198T1 (el) | Ενωσεις πυριδαζινονης | |
| TH162570B (th) | สารประกอบไพริดาซิโนน | |
| TH128131A (es) | ||
| TH168483A (th) | อนุพันธ์ของอิมิแดโซ-ไทรแอซีน เป็นตัวยับยั้ง pde10 |